NCT00087724

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 510 (planned)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	FK962

Timeline

• Start date: 2004-07-01
• Completion: 2006-09-01
• First posted: 2004-07-14
• Last updated: 2012-06-07

Locations

84 sites across 2 countries: United States, Canada